Showing results (1-10 of 714) with videos related to
Sort By:
Pageof 72
Blood|January 9, 2024
Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitorsLukas Veltmaat, Jorge CortesCurrent Opinion in Hematology|February 4, 2006
Overcoming drug resistance in chronic myeloid leukemiaJorge CortesHematology/Oncology Clinics of North America|July 24, 2004
Natural history and staging of chronic myelogenous leukemiaJorge CortesCurrent Hematology Reports|August 7, 2003
CMML: a biologically distinct myeloproliferative diseaseJorge CortesHematology. American Society of Hematology. Education Program|December 4, 2020
How to manage CML patients with comorbiditiesJorge CortesJournal of Hematology & Oncology|November 14, 2024
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AMLJorge CortesClinical Lymphoma|October 15, 2003
Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromesJorge CortesJournal of the National Comprehensive Cancer Network : JNCCN|August 9, 2008
BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choicesHagop Kantarjian, Jorge CortesBlood|March 18, 2025
Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: does dose matter?Mark Dalgetty, Jorge CortesPageof 72